Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on oncology that became publicly traded through a SPAC merger with Brookline Capital Acquisition Corp, sponsored by Brookline Capital Markets, completing the transaction in 2022. The company's pipeline centered on antibody-based cancer therapies, including its lead asset sotigalimab, an anti-CD40 agonist. The August 2023 8-K filing, accession number 0000950170-23-044038, reflects continued SEC reporting obligations during a period in which Apexigen was evaluating strategic alternatives amid challenging clinical and financing conditions. For full filing history, sponsor details, and deal analytics on Apexigen and hundreds of other SPAC transactions, sign up for complete data access at SpacDesk.